Drug Profile
Ad26 COV2 S - Johnson & Johnson Innovative Medicine
Alternative Names: 'Wuhan coronavirus vaccine - Johnson & Johnson Innovative Medicine; 2019-nCoV vaccine - Johnson & Johnson Innovative Medicine; Ad26 COVS1; Ad26-S.PP; Ad26.COV2 S; Ad26.COV2-S recombinant - Johnson & Johnson Innovative Medicine; Ad26.COV2.S; Coronavirus vaccine - Johnson & Johnson Innovative Medicine; Janssen COVID-19 Vaccine; Jcoviden; JNJ-78436735; Johnson & Johnson COVID-19 vaccine; Single-dose COVID-19 vaccine - Johnson & Johnson Innovative Medicine; Single-Shot Janssen COVID-19 Vaccine; VAC 31518Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Janssen Pharmaceuticals
- Developer Janssen Vaccines and Prevention B.V; Johnson & Johnson Innovative Medicine
- Class COVID-19 vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 24 Nov 2023 Janssen Vaccines & Prevention B.V.completes a phase II trial for COVID-2019 infection (Prevention) in South Africa, Spain, and USA (IM) (NCT04765384)
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 14 Aug 2023 Janssen Vaccines & Prevention completes a phase II trial in COVID-2019 infections (In adolescents, Prevention) in Brazil, Argentina, India, Mexico, South Africa (IM) (NCT05007080)